Sonnet BioTherapeutics Holdings, Inc.
Index- P/E- EPS (ttm)-6.84 Insider Own2.53% Shs Outstand7.93M Perf Week-6.09%
Market Cap8.20M Forward P/E- EPS next Y-0.95 Insider Trans0.00% Shs Float7.23M Perf Month-6.09%
Income-29.70M PEG- EPS next Q-1.10 Inst Own3.50% Short Float / Ratio4.69% / 0.11 Perf Quarter-44.04%
Sales0.30M P/S27.32 EPS this Y52.00% Inst Trans3.10% Short Interest0.34M Perf Half Y-72.89%
Book/sh-0.57 P/B- EPS next Y26.50% ROA-242.10% Target Price18.90 Perf Year-76.41%
Cash/sh0.41 P/C2.64 EPS next 5Y- ROE-513.60% 52W Range0.91 - 9.37 Perf YTD-6.09%
Dividend- P/FCF- EPS past 5Y53.00% ROI- 52W High-88.48% Beta0.58
Dividend %- Quick Ratio0.70 Sales past 5Y-61.50% Gross Margin- 52W Low18.42% ATR0.12
Employees12 Current Ratio0.70 Sales Q/Q-80.00% Oper. Margin- RSI (14)43.13 Volatility9.86% 11.30%
OptionableNo Debt/Eq- EPS Q/Q31.80% Profit Margin- Rel Volume0.29 Prev Close1.15
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume2.99M Price1.08
Recom1.50 SMA20-13.29% SMA50-3.77% SMA200-58.46% Volume861,293 Change-6.09%
Feb-01-23 08:00AM
Jan-19-23 08:00AM
Jan-09-23 08:00AM
Dec-15-22 04:05PM
Nov-02-22 08:00AM
04:05PM Loading…
Nov-01-22 04:05PM
Oct-31-22 07:30AM
Oct-04-22 08:00AM
Sep-26-22 08:00AM
Sep-21-22 08:00AM
Sep-16-22 08:30AM
Aug-15-22 04:05PM
Jul-22-22 07:00AM
Jul-21-22 07:30AM
Jun-09-22 07:00AM
09:25AM Loading…
Jun-02-22 09:25AM
May-10-22 08:15AM
Apr-13-22 07:00AM
Apr-08-22 01:05PM
Mar-16-22 07:00AM
Feb-09-22 06:30AM
Feb-08-22 07:00AM
Dec-20-21 12:58PM
Dec-17-21 06:30AM
Aug-30-21 04:01PM
Aug-19-21 09:35PM
Aug-16-21 06:30AM
Jun-14-21 07:45AM
Jun-08-21 04:30PM
May-17-21 07:00AM
06:30AM Loading…
May-10-21 06:30AM
May-03-21 06:00AM
Mar-29-21 04:30PM
Mar-22-21 07:00AM
Feb-16-21 08:10AM
Feb-03-21 06:30AM
Feb-01-21 06:30AM
Jan-25-21 06:30AM
Dec-17-20 06:30AM
Nov-30-20 08:30AM
Sep-01-20 08:30AM
Aug-25-20 07:30AM
Aug-24-20 07:37AM
Aug-14-20 07:30AM
Aug-04-20 07:35AM
Jul-20-20 07:30AM
Jul-15-20 07:30AM
May-18-20 07:30AM
Apr-06-20 07:30AM
Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.